L04AC08 · Antineoplastic and immunomodulating agents
Rilonacept Regeneron (previously Arcalyst)
Indications
Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.
Composition
- Active substance
- rilonacept
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rilonacept Regeneron (previously Arcalyst)
- Active substance
- rilonacept
- ATC code
- L04AC08
- Therapeutic area
- Cryopyrin-Associated Periodic Syndromes
- Marketing authorisation holder